Clinical Spectrum and Outcome of Patients with Graves’ Disease: A Single-Center Experience from a Tertiary Care Institution in the Kashmir Valley, India

作者
Mohammad Hayat Bhat,Javaıd Ahmad Bhat,Shariq Rashid Masoodi,Waseem Qureshi,Junaid Rashid Dar,Moomin Hussain Bhat
标识
DOI:10.25179/tjem.2020-77446
摘要

ABSTRACT Objective: Graves’ disease (GD) is a common autoimmune disorder with variable outcomes. We aim to study the clinical manifestations and treat-ment outcome of GD in the post-iodization scenario. Material and Met-hods: The present study was designed as a cross-sectional study, in which a total of 180 patients with GD (127 females and 53 males) attending our center were reviewed retrospectively. The demographic data, modes of tre-atment, comorbidities, remission, and recurrence rates were determined for the patients. All patients were initially treated with antithyroid drugs (ATDs), with the subsequent management depending on the course of the disease. Results: The mean (±SD) age at diagnosis was 38.30 (10.73) years and the lag period between the onset of symptoms and the diagno-sis was 5.12 (2.69) months, with the male patients having a significantly shorter duration of illness compared to females (4.36 vs. 5.44 months; P=0.015). Majority of the patients presented with the typical symptoms and signs associated with hyperthyroidism and/ or goiter, although the aty-pical presentations were not uncommon. ATDs were the most preferred treatment modality employed to achieve clinical and biochemical remis-sion. The mean duration of achieving euthyroidism and the normalization of TSH levels were 3.31±1.51 and 7.45±3.35 months, respectively. On fol-low-up at three months, 46.1% of the patients were euthyroid, with nor-malization of the TSH levels in 15.6% of them. Failure to achieve early remission/disease control was significantly higher in males (p=0.003) and smokers (p=0.036). Among the 72 patients who completed medical the-rapy, 49 patients achieved remission, of whom 20 patients relapsed with a first-year relapse rate of 20.4%. Disease relapse was significantly asso-ciated with higher initial 99 mTechnetium (99mTc) uptake (p=0.022) and higher grade of goiter (p=0.026) at presentation. The logistic regression analysis revealed male gender (p=0.048) and orbitopathy (p=0.036) as the independent risk factors predicting relapse of the GD. Conclusion: Graves’ disease manifests with varied clinical manifestations, including the atypical ones, warranting careful clinical assessment to ensure an accu-rate diagnosis. Gender and orbitopathy are the independent risk factors predicting the relapse of the disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
简亓完成签到,获得积分10
2秒前
幽默的迎天完成签到,获得积分10
2秒前
3秒前
胜似闲庭信步完成签到,获得积分10
3秒前
尾巴尖尖完成签到,获得积分10
4秒前
吴旭东完成签到,获得积分10
4秒前
无辜梨愁完成签到 ,获得积分10
5秒前
在下厉飞雨完成签到,获得积分20
6秒前
08153227完成签到,获得积分10
6秒前
kk完成签到 ,获得积分10
6秒前
nhanvm完成签到,获得积分10
10秒前
Akim应助犹豫的大碗采纳,获得10
12秒前
chenguanyiren完成签到 ,获得积分10
14秒前
小猴子完成签到 ,获得积分10
14秒前
LTJ完成签到,获得积分10
14秒前
hjjjj完成签到,获得积分10
15秒前
vothuong完成签到,获得积分10
15秒前
折光完成签到 ,获得积分10
15秒前
ChangShengtzu完成签到 ,获得积分10
16秒前
秋殤完成签到 ,获得积分10
16秒前
杨颖完成签到,获得积分10
17秒前
2010完成签到,获得积分10
18秒前
受不了12345完成签到,获得积分10
18秒前
所爱皆在完成签到 ,获得积分10
19秒前
dra7vu完成签到,获得积分10
19秒前
东风即是东风完成签到,获得积分10
19秒前
贲孱完成签到,获得积分10
20秒前
体贴洋葱完成签到 ,获得积分10
20秒前
博思好行完成签到,获得积分10
21秒前
寒冷半雪完成签到,获得积分10
21秒前
21秒前
激昂的觅松完成签到 ,获得积分10
21秒前
落雨冥完成签到,获得积分10
22秒前
闪闪应助酷然采纳,获得10
22秒前
XS_QI完成签到 ,获得积分10
25秒前
纪言七许完成签到 ,获得积分10
27秒前
28秒前
sun完成签到,获得积分10
29秒前
山蒲完成签到 ,获得积分10
30秒前
齐天小圣完成签到 ,获得积分10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Principles of town planning: translating concepts to applications 1000
Navigating Normative Orders. Interdisciplinary Perspectives 800
1 Peter and Christ's Descent to the Dead in Its Early Christian Reception 700
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7738991
求助须知:如何正确求助?哪些是违规求助? 9287933
关于积分的说明 20185229
捐赠科研通 7316956
什么是DOI,文献DOI怎么找? 3306016
关于科研通互助平台的介绍 2458519
邀请新用户注册赠送积分活动 2315956